ROR1 contributes to melanoma cell growth and migration by regulating N-cadherin expression via the PI3K/Akt pathway

Molecular Carcinogenesis

Volumn 55, Issue 11, 2016, Pages 1772-1785

  Fernández, Natalia Brenda ^a   Lorenzo, Daniela ^a   Picco, María Elisa ^a   Barbero, Gastón ^b   Dergan Dylon, Leonardo Sebastián ^a   Marks, María Paula ^a   García Rivello, Hernán ^c   Gimenez, Liliana ^d   Labovsky, Vivian ^a   Grumolato, Luca ^e   Lopez Bergami, Pablo ^a,b  

^a Consejo Nacional de Investigaciones Científicas y Técnicas ^*  (Argentina)

^b DEPARTAMENTO DE CIENCIAS NATURALES Y ANTROPOLOGÍA   (Argentina)

^c HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^d Instituto de Oncologia Angel H Roffo   (Argentina)

^e UNIVERSITY OF ROUEN   (France)

Author keywords

Akt; melanoma; migration; N cadherin; ROR1

Indexed keywords

DISHEVELLED 2; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; WNT3A PROTEIN; WNT5A PROTEIN; CADHERIN; ROR1 PROTEIN, HUMAN;

A375 CELL LINE; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER TISSUE; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; COLONY FORMING UNIT; CONTROLLED STUDY; DNA MICROARRAY; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOMA CELL; PHENOTYPE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WNT SIGNALING PATHWAY; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; METABOLISM; PATHOLOGY; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE;

CADHERINS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84949257698     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22426     Document Type: Article

References (48)

1. Girotti MR, Saturno G, Lorigan P, Marais R. No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. Mol Oncol 2014; 8:1140–1158.
2. Johnson DB, Sosman JA. Update on the targeted therapy of melanoma. Curr Treat Options Oncol 2013; 14:280–292.
3. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141:1117–1134.
4. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353:172–187.
5. Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, et al. The receptor tyrosine kinase ROR1—An oncofetal antigen for targeted cancer therapy. Semin Cancer Biol 2014; 29C:21–31.
6. Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem 1992; 267:26181–26190.
7. Matsuda T, Nomi M, Ikeya M, et al. Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development. Mech Dev 2001; 105:153–156.
8. Lyashenko N, Weissenbock M, Sharir A, Erben RG, Minami Y, Hartmann C. Mice lacking the orphan receptor ror1 have distinct skeletal abnormalities and are growth retarded. Dev Dyn 2010; 239:2266–2277.
9. Berger C, Sommermeyer D, Hudecek M, et al. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res 2014; 3:206–216.
10. Nomi M, Oishi I, Kani S, et al. Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: Redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases. Mol Cell Biol 2001; 21:8329–8335.
11. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 2008; 123:1190–1195.
12. Fukuda T, Chen L, Endo T, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA 2008; 105:3047–3052.
13. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194:1625–1638.
14. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194:1639–1647.
15. Shabani M, Asgarian-Omran H, Jeddi-Tehrani M, et al. Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour Biol 2007; 28:318–326.
16. Shabani M, Asgarian-Omran H, Vossough P, et al. Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms’ tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leuk Lymphoma 2008; 49:1360–1367.
17. Yamaguchi T, Yanagisawa K, Sugiyama R, et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 2012; 21:348–361.
18. Rabbani H, Ostadkarampour M, Danesh Manesh AH, Basiri A, Jeddi-Tehrani M, Forouzesh F. Expression of ROR1 in patients with renal cancer-a potential diagnostic marker. Iran Biomed J 2010; 14:77–82.
19. Zhang S, Chen L, Cui B, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PloS ONE 2012; 7:e31127.
20. Hojjat-Farsangi M, Ghaemimanesh F, Daneshmanesh AH, et al. Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells. PloS ONE 2013; 8:e61167.
21. Cui B, Zhang S, Chen L, et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res 2013; 73:3649–3660.
22. Serra R, Easter SL, Jiang W, Baxley SE. Wnt5a as an effector of TGFbeta in mammary development and cancer. J Mammary Gland Biol Neoplasia 2011; 16:157–167.
23. O'Connell MP, Marchbank K, Webster MR, et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 2013; 3:1378–1393.
24. Shibamoto S, Higano K, Takada R, Ito F, Takeichi M, Takada S. Cytoskeletal reorganization by soluble Wnt-3a protein signalling. Genes Cells 1998; 3:659–670.
25. Lopez-Bergami P, Habelhah H, Bhoumik A, Zhang W, Wang LH, Ronai Z. RACK1 mediates activation of JNK by protein kinase C [corrected]. Mol Cell 2005; 19:309–320.
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248–254.
27. Widmer DS, Cheng PF, Eichhoff OM, et al. Systematic classification of melanoma cells by phenotype-specific gene expression mapping. Pigment Cell Melanoma Res 2012; 25:343–353.
28. Bogunovic D, O'Neill DW, Belitskaya-Levy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 2009; 106:20429–20434.
29. Bryja V, Schulte G, Rawal N, Grahn A, Arenas E. Wnt-5a induces dishevelled phosphorylation and dopaminergic differentiation via a CK1-dependent mechanism. J Cell Sci 2007; 120:586–595.
30. Gonzalez-Sancho JM, Brennan KR, Castelo-Soccio LA, Brown AM. Wnt proteins induce dishevelled phosphorylation via an LRP5/6- independent mechanism, irrespective of their ability to stabilize beta-catenin. Mol Cell Biol 2004; 24:4757–4768.
31. Cavallaro U, Christofori G. Cell adhesion in tumor invasion and metastasis: Loss of the glue is not enough. Biochim Biophys Acta 2001; 1552:39–45.
32. Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PloS ONE 2010; 5:e11859.
33. Zhang S, Chen L, Wang-Rodriguez J, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol 2012; 181:1903–1910.
34. Zhang H, Qiu J, Ye C, et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep 2014; 4:5811.
35. Hojjat-Farsangi M, Khan AS, Daneshmanesh AH, et al. The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. PloS ONE 2013; 8:e78339.
36. Bicocca VT, Chang BH, Masouleh BK, et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 2012; 22:656–667.
37. Daneshmanesh AH, Hojjat-Farsangi M, Moshfegh A, et al. The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies. Br J Haematol 2015; 169:455–458.
38. Forrester WC, Kim C, Garriga G. The Caenorhabditis elegans Ror RTK CAM-1 inhibits EGL-20/Wnt signaling in cell migration. Genetics 2004; 168:1951–1962.
39. Tseng HC, Kao HW, Ho MR, et al. Cytoskeleton network and cellular migration modulated by nuclear-localized receptor tyrosine kinase R OR1. Anticancer Res 2011; 31:4239–4249.
40. Caramel J, Papadogeorgakis E, Hill L, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 2013; 24:466–480.
41. Boyd SC, Mijatov B, Pupo GM, et al. Oncogenic B-RAF (V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion. J Invest Dermatol 2012; 133:1269–1277.
42. Katoh M, Katoh M. Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades. Int J Mol Med 2009; 23:763–769.
43. Anastas JN, Kulikauskas RM, Tamir T, et al. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Invest 2014; 124:2877–2890.
44. Endo M, Nishita M, Fujii M, Minami Y. Insight into the role of wnt5a-induced signaling in normal and cancer cells. Int Rev Cell Mol Biol 2015; 314:117–148.
45. Hojjat-Farsangi M. Small-molecule inhibitors of the receptor tyrosine kinases: Promising tools for targeted cancer therapies. Int J Mol Sci 2014; 15:13768–13801.
46. Baskar S, Wiestner A, Wilson WH, Pastan I, Rader C. Targeting malignant B cells with an immunotoxin against ROR1. MAbs 2012; 4:349–361.
47. Daneshmanesh AH, Hojjat-Farsangi M, Khan AS, et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia 2011; 26:1348–1355.
48. Choi MY, Widhopf GF, 2nd, Wu CC et al. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin Lymphoma Myeloma Leuk 2015; 15:S167–S169.